Talent Pool

Contributed by:

NOTE: The content below contains the first few paragraphs of the printed article and the titles of the sidebars and boxes, if applicable.

Pharma POOL

Dr. Mike BURGESS, Roche
Dr. Mikael DOLSTEN, Pfizer
Kenneth FRAZIER, Merck

Biotechnology POOL
Robert BRADWAY, Amgen
Dr. Henry LI, Kylin Therapeutics
Kenneth MOCH, Chimerix
Dr. George PAINTER, Chimerix
Dr. Thomas PITLER, Chimerix

Biopharmaceutical POOL Dr. John ALAM, Inhibitex Dr. Sol BARER, Celgene Robert HUGIN, Celgene Dr. Michael CHANG, Optimer Pharmaceuticals Pedro LICHTINGER, Optimer Pharmaceuticals Dr. Orville KOLTERMAN, Amylin Pharmaceuticals Dr. Christian WEYER, Amylin Pharmaceuticals Dr. Tom NOVAK, Fate Therapeutics Lee RAUCH, Nuon Therapeutics Dr. Mark THORNTON, Novavax Specialty POOL Frank CONDELLA Jr., Columbia Laboratories Richard KING, AcelRx Pharmaceuticals Robert LORETTE, The Global Alliance for TB Drug Development Martin MARION, Cobalis Dr. Pamela VIG, Presidio Pharmaceuticals Device/Diagnostic POOL Dr. Maher ALBITAR, Health Discovery Dr. Jonathan KNOWLES, Caris Life Sciences Charles (Chas) MCKHANN, Apnex Medical Dr. Dana WASHBURN, Lantheus Medical Imaging Discovery POOL Robert FORRESTER, Forma Therapeutics Genomics POOL Louise GRANT, Expression Analysis Dr. Patrick HURBAN, Expression Analysis Emerging POOL Dr. Ronnda BARTEL, Aastrom Biosciences Dr. Sharon WATLING, Aastrom Biosciences Raul RODRIGUEZ, Rigel Pharmaceuticals Dolly VANCE, Rigel Pharmaceuticals Association POOL Dr. Frank CASTY, AstraZeneca Agency POOL Christine ABBOTT, MS&LGroup Ellena FRIEDMAN, MS&LGroup Trine HINDKLEV, MS&LGroup Mike HUCKMAN, MS&LGroup Anita MANNING, MS&LGroup Jeff YOUNG, MS&LGroup Blythe ALPERN, Goble & Associates Bil BOYD, Goble & Associates Brooke CLAUSSEN, Goble & Associates Tara GILL, Goble & Associates Brian HANNAH, Goble & Associates Terry LAWRENCE, Goble & Associates Alicia WILLIS, Goble & Associates Tom BUHRMANN, Topin & Associates Kimberly CLOTMAN, Roska Healthcare Jenni CRAWFORD, Roska Healthcare Paul SEGAL, Roska Healthcare Joe VITALE, Roska Healthcare Hayne CROOKS, AbelsonTaylor Tristen GEORGE, AbelsonTaylor Denise JOSEPH, AbelsonTaylor Andrea KARTLEY, AbelsonTaylor Shari NEAL, AbelsonTaylor Bejan SEVVOM, AbelsonTaylor David ROSEN, HealthStar PR Gregory TARMIN, HealthStar PR Shelly WEITZ, MicroMass Communications Consulting POOL Rena GOINS, D2 Pharma Consulting Craig HALVERSON, Biologics Consulting Group Brian MONDRY, Kantar Health Philippe POULIOT, The Research Partnership CRO POOL Dr. J. Michael HAMILTON, INC Research David SPAIGHT, WIL Research Company Hans THUNEM, Harlan Laboratories Media POOL Dina CONWAY, Quadrant HealthCom Service POOL Melissa CABRAL, MediciGlobal Mani CHIDAMBARAM, Preceptiv Learning Solutions Dr. Anthony CHILTON, Bioanalytical Systems Michael MICKENS, Sentrx Lauren STEWART, Sentrx Technology POOL Lauren BARNETT, NXLevel Solutions Alan HORGAN, Firecrest Clinical Beverly HUDSON, OmniComm Systems Stephen JOHNSON, OmniComm Systems Kenneth LIGHT, OmniComm Systems Angela MICCOLI, Cegedim Dendrite Chris TAMA, Qforma Charlie WALKER, Cadient Group Pharma POOL Dr. Mike BURGESS Roche Appoints Head of Oncology Discovery Global pharmaceutical and diagnostics company Roche has named Mike Burgess, M.D., Ph.D., head of its oncology discovery and translational area (DTA). The oncology DTA is one of five disease-focused organizations at Roche and, as part of the pharma research and early development (pRED) organization, oversees oncology research and development from early to late-stage. Dr. Burgess has been with Roche since 2006, most recently as head of academic alliances, which is part of pRED. A physician scientist with specialist clinical experience in pediatrics and pediatric oncology, Dr. Burgess received his medical training and a Ph.D. in molecular biology from the University of Bristol in the United Kingdom. Dr. Mikael DOLSTEN Pfizer Completes Restructuring of R&D Functions Global healthcare company Pfizer has appointed Mikael Dolsten, M.D., Ph.D., president of Pfizer Worldwide Research & Development as the company completes its integration of these functions following the Wyeth acquisition. Dr. Dolsten previously led Wyeth’s research and development organization and, after the close of the Wyeth acquisition, was named president of Pfizer’s BioTherapeutics Research & Development. Through the newly named Pfizer Worldwide Research & Development organization, Dr. Dolsten now leads all research at Pfizer, as well as development of all compounds through Phase II, or proof-of-concept. Late-stage clinical development continues to be led by clinical teams throughout Pfizer’s worldwide biopharmaceutical businesses. Pfizer Worldwide Research & Development’s structure includes biotherapeutics research and development, focused on large molecules and biotechnologies; pharmatherapeutics research and development, focused on small molecules; and vaccines research and development. Dr. Dolsten earned a Ph.D. in tumor immunology and an M.D., both from the Medical Faculty, University of Lund in Sweden. Kenneth FRAZIER Adam SCHECHTER Merck Announces Leadership Shifts Merck has announced changes in responsibilities for its top leaders. Kenneth Frazier has been promoted to company president, leading Merck’s three largest worldwide divisions responsible for pharmaceutical and vaccine sales and marketing, research and development, and manufacturing and supply. Mr. Frazier succeeds Richard Clark, who continues to head Merck as chairman and CEO. As president of global human health, Mr. Frazier played a key role in Merck’s 2009 merger with Schering-Plough and led the implementation of important improvements in the efficiency and effectiveness of the company’s worldwide sales and marketing organization. Succeeding Mr. Frazier as president of global human health is Adam Schechter, who previously led Merck’s pharmaceutical business in the United States. Mr. Schechter is responsible for leading the company’s worldwide sales and marketing business for pharmaceutical medicines and vaccines. Biotechnology POOL Robert BRADWAY Amgen Appoints President Global biotechnology firm Amgen has appointed Robert Bradway president and chief operating officer. Mr. Bradway is responsible for Amgen’s global commercial operations, manufacturing operations, strategy and corporate development, information technology, global government affairs, and compliance. He joined Amgen in 2006 and most recently served as executive VP and chief financial officer. Dr. Henry LI Kylin Therapeutics Names R&D Director Kylin Therapeutics has named Henry Li, Ph.D., to the newly created position of director for the company’s research and development team. Kylin is a biotechnology company that employs an RNA nanoparticle technology platform called pRNA to exploit the enormous potential of oligonucleotides for treatment of many common diseases Dr. Li is trained in molecular virology and cancer research and brings to Kylin more than 13 years of biopharmaceutical research and development experience, including positions at Immusol/iTherx Pharmaceuticals and NexBio. He received a Ph.D. from The University of California, Irvine, and postdoctoral training at UCLA School of Medicine. Kenneth MOCH Dr. George PAINTER Dr. Thomas PITLER Chimerix Announces CEO Transition Chimerix, a biotechnology company developing orally available antiviral therapeutics, has promoted Kenneth Moch to president and CEO. Mr. Moch has served as Chimerix’s chief operating officer since joining the company in July 2009. He has an MBA from the Stanford Graduate School of Business. As president and CEO, Mr. Moch succeeds George Painter, Ph.D., who has been named chairman and chief scientific officer, overseeing Chimerix’s drug discovery and development efforts and seeking opportunities to leverage the company’s proprietary platform capabilities and antiviral expertise in the advancement of important new medicines that address global health needs. Dr. Painter received an M.S. in physical organic chemistry and a Ph.D. in synthetic chemistry, both from Emory University. In other moves, Thomas Pitler, Ph.D., has joined Chimerix in the newly created position of VP, business development, with overall responsibility for advancing the company’s pipeline of proprietary oral antiviral therapeutics as it transitions to a development-stage company. Dr. Pitler has more than 25 years of experience, combining skills in business development and strategic planning with a strong scientific and financial background. He was most recently senior VP, chief business and financial officer at Neurogen, which was recently acquired by Ligand Pharmaceuticals. Dr. Pitler received a Ph.D. in physiology from Wake Forest University. Biopharmaceutical POOL Dr. John ALAM Inhibitex Adds Senior Medical Advisor Inhibitex, a biopharmaceutical company focused on developing products to prevent and treat serious infectious diseases, has named John Alam, M.D., senior medical advisor, with responsibility for formulating and directing the clinical and regulatory strategies for Inhibitex’s development programs. Dr. Alam was previously executive VP, medicines development and chief medical officer for Vertex Pharmaceuticals. He holds an M.D. from Northwestern University’s Feinberg School of Medicine. Dr. Sol BARER Robert HUGIN Celgene Announces Management Shift Celgene has appointed Sol Barer, Ph.D., executive chairman, and has named Robert Hugin to succeed Dr. Barer as CEO. Mr. Hugin has been with Celgene since 1999 and most recently served as president and chief operating officer. Celgene is an integrated global pharmaceutical company engaged primarily in the discovery, development, and commercialization of innovative therapies for the treatment of cancer and inflammatory diseases through gene and protein regulation. Dr. Michael CHANG Pedro LICHTINGER Pfizer Veteran Joins Optimer Pharmaceuticals as CEO Optimer Pharmaceuticals has announced that Co-founder Michael Chang, Ph.D., has stepped down as president and CEO and assumed the role of chairman and consultant. Former Pfizer executive Pedro Lichtinger succeeds Dr. Chang as president and CEO of Optimer, a biopharmaceutical company focused on discovering, developing, and commercializing innovative anti-infectives to treat serious infections and address unmet medical needs. Mr. Lichtinger has more than 30 years of global business experience in the pharmaceutical and animal health industries. Before joining Optimer, he spent 14 years at Pfizer, where he most recently served as president of the company’s global primary care business unit. Mr. Lichtinger holds an MBA from the Wharton School of the University of Pennsylvania. Dr. Orville KOLTERMAN Dr. Christian WEYER Amylin Announces R&D Promotions Amylin Pharmaceuticals has made leadership changes to strengthen the biopharmaceutical company’s focus on preparations for a new product launch and the advancement of its late-stage development programs. Orville Kolterman, M.D., has been promoted to senior VP, chief medical officer, from senior VP, research and development. Dr. Kolterman retains responsibility for global safety activities and continues to lead interactions with regulatory agencies. Dr. Kolterman received an M.D. from Stanford University School of Medicine. Christian Weyer, M.D., has been appointed senior VP, research and development, from VP, medical development. Dr. Weyer now leads Amylin’s R&D organization, focusing on expanding opportunities with the company’s existing diabetes products, advancing the obesity and early diabetes pipeline, and driving research programs that support innovation and business growth. Dr. Weyer received an M.D. and clinical training from the Department of Metabolic Disorders, World Health Organization Collaborating Center for Diabetes Treatment and Prevention, at the University of Düsseldorf in Germany. He also holds a postdoctoral master’s degree in advanced clinical research from the University of California, San Diego. Dr. Tom NOVAK Former Roche Executive Becomes Fate Therapeutics’ Research VP Fate Therapeutics has appointed Tom Novak, Ph.D., VP of research and drug discovery, with focus on advancing the biopharmaceutical company’s pipeline of stem cell modulators: small molecules or biologics that guide cell fate in vivo for therapeutic benefit. Dr. Novak brings to Fate more than 15 years of experience working with large pharmaceutical companies, most recently as senior director and head of discovery technologies at Roche. He received a Ph.D. in biology from the California Institute of Technology and performed his postdoctoral training in immunobiology at Yale University School of Medicine. Lee RAUCH Nuon Therapeutics Names CEO Lee Rauch has been appointed president and CEO of Nuon Therapeutics, a privately held, clinical-stage biopharmaceutical company developing small-molecule drugs to address critical, unmet medical needs in autoimmune and rheumatic diseases. Ms. Rauch’s career includes key executive roles in corporate development, corporate finance, product development, and strategic marketing. Recently, she held the position of acting head of corporate development for Onyx Pharmaceuticals. Dr. Mark THORNTON Novavax Selects Medical Chief Novavax has appointed Mark Thornton, M.D., MPH, Ph.D., senior VP, development and chief medical officer. Dr. Thornton was most recently senior VP of product development at GenVec. He received his medical and doctorate degrees from West Virginia University and his master’s in public health from Johns Hopkins University’s School of Public Health, where he also completed a clinical pharmacology fellowship. Novavax is a clinical-stage biopharmaceutical company creating novel vaccines to address a broad range of infectious diseases worldwide, including H1N1, using advanced proprietary virus-like-particle (VLP) technology. Specialty POOL Frank CONDELLA Jr. Columbia Laboratories Names Chief Executive Columbia Laboratories has appointed Frank Condella Jr. president and CEO. Mr. Condella had been serving as interim CEO of Columbia, a specialty pharmaceutical company focused on developing and commercializing products for the women’s healthcare and endocrinology markets that use its novel bioadhesive drug delivery technology. Mr. Condella earned an MBA from Northeastern University. Richard KING AcelRx Appoints CEO AcelRx Pharmaceuticals has named Richard King president and CEO, responsible for leading AcelRx’s efforts to advance its portfolio of products using its NanoTab platform technology. Mr. King was previously president and general manager of Tercica. AcelRx is developing novel products that address unmet needs in postoperative pain and cancer breakthrough pain, as well as a first-in-class mild sedation, anxiolysis, and analgesia product with fast onset for office-based therapeutic and diagnostic procedures. Robert LORETTE TB Alliance Names Business Development VP The Global Alliance for TB Drug Development (TB Alliance), a not-for-profit product development partnership (PDP) accelerating the discovery and development of new drugs to fight tuberculosis (TB), has appointed Robert Lorette, senior VP of business development. Mr. Lorette is helping to lead the TB Alliance’s efforts to establish agreements and strategic alliances within the context of the PDP business model. Most recently, Mr. Lorette founded and was president and CEO of Boston Life Science Advisor. He received a master’s degree in public administration from the Maxwell School of Syracuse University and a law degree from Syracuse University College of Law. Martin MARION Cobalis Makes Leadership Changes Cobalis, a specialty pharmaceutical, nutraceutical, and preventive healthcare product development and marketing company, has appointed Martin Marion CEO. Mr. Marion’s responsibilities include accelerating the marketing of PreHistin, the company’s flagship anti-allergy product. Mr. Marion was formerly chief marketing officer for Cobalis from 2003 through 2006, and for the past year has served as a consultant to the company as it prepared to launch PreHistin. Dr. Pamela VIG Presidio Strengthens Research Team Presidio Pharmaceuticals has hired Pamela Vig, Ph.D., as senior director of clinical research as the specialty company enters into a series of clinical trials for its lead hepatitis C virus (HCV) NS5A inhibitor, PPI-461. Dr. Vig brings to Presidio more than 16 years of experience in clinical drug development and program management, most recently as director, global medical affairs, for Johnson & Johnson Pharmaceutical Services in London. She received both an M.Phil and a Ph.D. from Imperial College London in the departments of hepatology and pathology. Presidio Pharmaceuticals is focused on the discovery, in-licensing, development, and commercialization of novel therapeutics for viral infections, including HIV-1 and HCV. Device/Diagnostic POOL Dr. Maher ALBITAR Cancer Expert Joins Health Discovery as Medical Chief Health Discovery, a molecular diagnostics company operating primarily in the emerging field of personalized medicine, has appointed world-renowned cancer scientist and inventor Maher Albitar, M.D., chief medical officer. Dr. Albitar is responsible for leading Health Discovery’s molecular diagnostic and medical imaging discovery, development, and commercialization program and helping to expand the company’s pipeline of molecular diagnostic and medical imaging tests for cancer using its patented Support Vector Machine technology. Dr. Albitar was most recently the medical director of hematology and oncology and chief of research and development at Quest Diagnostics Nichols Institute. He received an M.D. from Damascus Medical School in Syria and is board certified in anatomic and clinical pathology, with extensive experience in hematopathology. Dr. Jonathan KNOWLES Caris Life Sciences Appoints Scientific Chief Caris Life Sciences, a biosciences company specializing in the development and commercialization of anatomic pathology, molecular profiling, and blood-based diagnostic technologies, has named Vice Chairman Jonathan Knowles, Ph.D., to the additional role of chief scientific officer. Dr. Knowles is responsible for the expansion and globalization of the company’s overall scientific and research capabilities, as well as specific oversight for the development of novel and proprietary assays using the Carisome platform. He received his Ph.D. in genetics of mitochondria from the University of Edinburgh in Scotland. Charles (Chas) MCKHANN Apnex Taps Former Boston Scientific VP as CEO Apnex Medical, a pioneer in developing novel medical device treatments for obstructive sleep apnea, has named Charles (Chas) McKhann president and CEO. Mr. McKhann has extensive experience in healthcare, particularly medical devices, and was previously worldwide VP of marketing for the cardiac rhythm management division of Boston Scientific. He earned an MBA from Stanford University. Dr. Dana WASHBURN Lantheus Names Clinical Development VP Dana Washburn, M.D., has joined Lantheus Medical Imaging as VP, clinical development and medical affairs. Dr. Washburn is responsible for spearheading the clinical investigation of Lantheus’s pipeline of novel diagnostic imaging agents, providing ongoing medical and safety support for the company’s existing portfolio, and leading the company’s medical affairs department. He also is involved in product life-cycle management, including clinical trial oversight and the safety and surveillance of marketed products. Dr. Washburn most recently was VP, clinical trials and safety, and medical safety officer at Boston Scientific. He received a medical degree from the University of Massachusetts Medical School and is currently a fellow of the American College of Cardiology. Discovery POOL Robert FORRESTER Forma Therapeutics Names Operating Chief Robert Forrester has joined Forma Therapeutics as chief operating officer. Mr. Forrester has extensive experience in corporate operations and finance, corporate development, and public and private fundraising, most recently as interim president and CEO and chief financial officer of CombinatoRx. Forma Therapeutics is a biopharmaceutical company integrating transformative biology and chemistry to unlock targets and pathways that have been validated through genomic medicine as root causes or major drivers of human cancers. Genomics POOL Louise GRANT Dr. Patrick HURBAN Expression Analysis Strengthens Scientific Management Expression Analysis, a provider of genomic services for clinical trials and research, has named Louise Grant director of operations, with responsibility for managing and expanding laboratory capabilities. Ms. Grant has more than 20 years of experience in the clinical diagnostics industry, most recently as microbiology program director for bioMérieux. In other moves, Patrick Hurban, Ph.D., has joined Expression Analysis as VP of research and development. Dr. Hurban is responsible for a group of Ph.D. scientists with specialized genomics expertise charged with providing new application and new technology development support to Expression Analysis and its clients. His previous experience includes several positions of increasing responsibility in high-profile genomics-focused organizations. Dr. Hurban has a Ph.D. in human genetics from the University of Utah School of Medicine and performed his postdoctoral research at Stanford University School of Medicine. Emerging POOL Dr. Ronnda BARTEL Dr. Sharon WATLING Aastrom Biosciences Expands Clinical Management Aastrom Biosciences, a developer of autologous cellular therapies for the treatment of severe cardiovascular diseases, has promoted Ronnda Bartel, Ph.D., to chief scientific officer from VP of technical operations. Dr. Bartel is responsible for all company research, development, manufacturing, and engineering operations. In other moves, Sharon Watling, Pharm.D., has joined Aastrom as VP, clinical and regulatory. Dr. Watling coordinates and manages all aspects of the continued clinical development of Aastrom products. Previously she worked in clinical development at Pfizer. Raul RODRIGUEZ Dolly VANCE Rigel Announces Executive Promotions Rigel Pharmaceuticals, a clinical-stage company that discovers and develops novel, small-molecule drugs for the treatment of inflammatory/autoimmune, muscle, and metabolic diseases, has announced two senior management promotions. Chief Operating Officer Raul Rodriguez has been named to the additional role of president. Mr. Rodriguez joined Rigel in 2000 as VP, business development, and has served as executive VP and chief operating officer since 2004. Dolly Vance has been appointed general counsel and executive VP of corporate affairs. Ms. Vance joined Rigel in 2000 as the company’s first in-house counsel and was appointed general counsel and VP of intellectual property in 2003. Association POOL Dr. Frank CASTY AstraZeneca VP Named to HHS Healthcare Research and Quality Group Frank Casty, M.D., AstraZeneca’s VP of external medical relations, has been selected to serve as a member of the Agency for Healthcare Research and Quality’s (AHRQ), Effective Program Stakeholder Group. AHRQ is part of the U.S. Department of Health and Human Services (HHS) and is the nation’s leading federal agency for research on healthcare quality, costs, outcomes, and patient safety. As a member of the Effective Program Stakeholder Group, Dr. Casty champions objectivity, accountability, and transparency in the Effective Health Care Program and is responsible for providing input for program reports and summaries. He also recommends solutions to issues identified by AHRQ and identifies the information needs most useful to all healthcare stakeholders. The Effective Health Care Program helps patients, physicians, and other healthcare stakeholders make better treatment choices through three primary products: comparative effectiveness reviews that outline the benefits and harms of treatment options, technical briefs that explain what is known and not known about emerging health tests and treatment options, and original research reports that are based on clinical research and studies and explore the benefits and harms of treatments. Agency POOL Christine ABBOTT Ellena FRIEDMAN Trine HINDKLEV Mike HUCKMAN Anita MANNING Jeff YOUNG MS&LGroup Expands Healthcare Practice Global communications firm MS&LGroup has expanded its healthcare practice in North America with the addition of several senior leaders to augment its healthcare strategy and contribute to the creation of new products and services. Christine Abbott has been appointed a senior VP, healthcare, in MS&LGroup’s New York office, where she works on disease awareness education campaigns for the agency’s key clients. Ms. Abbott has more than 10 years of experience in conceiving and launching general market and multicultural grassroots programs for pharmaceutical companies. Ellena Friedman has joined MS&LGroup as a senior VP, director of the healthcare and life-sciences practice and deputy managing director in Boston. Previously, Ms. Friedman was a senior VP at Feinstein Kean Healthcare. Trine Hindklev has been named senior VP, media relations, with responsibility for providing strategic counsel for key accounts and overseeing MS&L Studios, a full-service production and media training consultancy. Ms. Hindklev has more than 15 years of experience developing national and global media relations campaigns for Fortune 500 companies. Before joining MS&LGroup, she oversaw the media relations network at Chandler Chicco Agency. Mike Huckman joins MS&LGroup as a senior VP and director of healthcare media strategy, providing senior media counsel and serving as a thought leader in the industry. Mr. Huckman previously covered the drug, biotechnology, and medical device industry for CNBC. The agency also has hired Anita Manning as a senior strategist, counseling clients, and providing messaging using a journalistic lens. Previously a reporter for USA Today, Ms. Manning is employing that skill set to provide insight and create the tools needed to remain competitive in the marketplace. Jeff Young has joined MS&LGroup as VP, editorial services for the healthcare practice. Mr. Young specializes in fusing the science and brand imperatives into compelling stories and providing communications counsel to support leading brands in the pharmaceutical, diagnostic, and medical devices industries. Mr. Young spent the past decade in senior editorial positions at top public relations agencies, most recently Burson-Marsteller. Blythe ALPERN Bil BOYD Brooke CLAUSSEN Tara GILL Brian HANNAH Terry LAWRENCE Alicia WILLIS Goble & Associates Makes Staff Changes Goble & Associates (GA), an independent, full-service communication agency specializing in healthcare has announced a number of promotions and new hires in response to growing client demand. Blythe Alpern has joined GA as a senior writer. Ms. Alpern was most recently a senior freelance copywriter for Integrative Logic. Bil Boyd has joined the agency as an associate creative director, from the same position at MedThink Communications. Brooke Claussen has been promoted to senior group creative director from group creative director. Ms. Claussen’s responsibilities have been expanded to manage more of the creative efforts across the department. Tara Gill has joined GA as a senior account manager. Ms. Gill was previously an account manager at RR Donnelley Premedia Technologies. Brian Hannah has been elevated to director of science and clinical support from senior writer. Mr. Hannah provides creative and clinical insights across agency accounts. Terry Lawrence has been promoted to associate creative director from senior art director. Alicia Willis has returned to GA as an art director. She originally joined the company as an art director in March 2009 after freelancing for the agency and resigned her position in September to pursue other artistic endeavors. Tom BUHRMANN Topin & Associates Strengthens Account Staff Full-service healthcare marketing communications agency Topin & Associates has appointed Tom Buhrmann senior account executive, working on brands for Teva Neuroscience and Lundbeck. Mr. Buhrmann was previously a senior account executive with Corbett Worldwide Healthcare Communications. Kimberly CLOTMAN Jenni CRAWFORD Paul SEGAL Joe VITALE Roska Healthcare Expands Creative, Account Teams Independent healthcare agency Roska Healthcare has appointed Kimberly Clotman account director for Bristol Myers-Squibb, one of the agency’s new account wins. Ms. Clotman joins Roska from McNeil Healthcare, where she was senior associate product director for Benadryl. Roska Healthcare has also made a number of additions to its creative team. The agency has added two senior copywriters to staff both new accounts and address organic growth on existing business. Jenni Crawford has joined the agency as senior copywriter on the Bristol-Myers Squibb account. Ms. Crawford’s previous experience includes stints at Digitas Health and Euro RSCG. Paul Segal has also joined Roska as senior copywriter, from the same position at Integrated Communications. Mr. Segal is working on several new accounts for Roska, including Pfizer, Bristol-Myers Squibb, and Cumberland Pharmaceuticals. Roska has named Joe Vitale creative director, primarily responsible for charting creative direction and overseeing creative activity for the agency’s clients. Mr. Vitale was most recently creative director with D.i.D. Hayne CROOKS Tristen GEORGE Denise JOSEPH Andrea KARTLEY Shari NEAL Bejan SEVVOM AbelsonTaylor Announces Promotions Independent healthcare advertising agency AbelsonTaylor has announced several recent promotions within its account and creative teams. Hayne Crooks has been promoted to senior account executive from account executive. Ms. Crooks is working on a product in the area of ophthalmology and optometry. She has been with AbelsonTaylor since 2006. Tristen George has been promoted to associate creative director, art, from senior art director. Ms. George is creating websites, online advertising, TV spots, and digital sales aids across a variety of brands within the interactive group, focusing on nutrition, diabetes, cardiology, and gastroesophageal reflux disease. She has been with AbelsonTaylor since 2008. The agency has promoted Denise Joseph to senior account executive from account executive, with responsibility for an oncology product. Ms. Joseph joined AbelsonTaylor in 2005. Andrea Kartley has been elevated to account executive from assistant account executive, with responsibility for products in the infant formula area. Ms. Kartley joined AbelsonTaylor in 2007. Shari Neal has been promoted to interactive developer from associate interactive developer, creating content, banner ads, interactive games, and custom applications across a wide range of brands. She has been with AbelsonTaylor since 2006. Bejan Sevvom has been promoted to senior account executive from account executive. Mr. Sevvom is working on a product for the treatment of osteoporosis. He has been with AbelsonTaylor since 2006. David ROSEN Gregory TARMIN HealthStar PR Expands Senior Management HealthStar PR (HSPR), a division of HealthStar Communications, has added two PR veterans to its senior management team. David Rosen has been named senior VP. Mr. Rosen has spent 17 years in pharmaceutical and healthcare public relations. He most recently was a senior manager at Meridian Health. Gregory Tarmin has joined HSPR as executive VP, general manager. A 20-year PR veteran, Mr. Tarmin was previously a senior VP at MS&L Worldwide. Shelly WEITZ MicroMass Adds Account Director MicroMass Communications, which specializes in behavioral science-based relationship marketing in the healthcare industry, has appointed veteran marketing strategist Shelly Weitz account director, with responsibility for the agency’s account with a large biotech and pharmaceutical services provider. Ms. Weitz has more than two decades of marketing communications experience, most recently as senior creative director for Creative Strategy. She holds an M.A. in English literature from the University of Pennsylvania. Consulting POOL Rena GOINS D2 Pharma Consulting Strengthens Specialty Markets Team Rena Goins has joined D2 Pharma Consulting as senior director, specialty markets. D2 provides strategic outsourced solutions to emerging and established companies for the commercialization, distribution, and marketing of pharmaceuticals, medical devices, and biotechnology pharmaceuticals. Ms. Goins serves as a major contributor to D2’s ongoing customer support, including products with REMS requirements. She joins D2 from Metro Medical Supply, where she launched a new specialty sales team. Craig HALVERSON BCG Strengthens Consulting Team Craig Halverson has joined regulatory affairs consulting firm Biologics Consulting Group (BCG) as a senior consultant. Mr. Halverson has more than 25 years of scientific, regulatory, and quality experience in the biopharmaceutical and in vitro diagnostics industries, and he most recently he was VP of regulatory affairs and quality assurance at SciClone Pharmaceuticals. He received an M.S. in experimental pathology from the University of Southern California. Brian MONDRY Kantar Health Strengthens Digital Solutions Team Kantar Health, a healthcare-focused global consultancy and marketing insights company, has appointed Brian Mondry VP, integrated strategy and digital solutions, helping clients to define, evaluate, and optimize traditional and digital/nontraditional marketing and media. Mr. Mondry’s 20 years of agency experience have included 12 years of substantial online focus, including six years with the online digital division of Grey Worldwide Advertising. Philippe POULIOT Research Partnership Adds U.S. Staff The Research Partnership, a London-based global pharmaceutical market research specialist, has appointed Philippe Pouliot an associate director in its Philadelphia office. Mr. Pouliot works within the U.S. account management team and is responsible for designing and executing global and U.S.-specific projects. Mr. Pouliot was previously project director at Genactis. CRO POOL Dr. J. Michael HAMILTON INC Research Expands Oncology Practice INC Research, a therapeutically focused CRO, has appointed J. Michael Hamilton, M.D., senior medical director in its oncology practice. Dr. Hamilton’s oncology and drug development expertise supports medical monitoring and team training and brings a consultative approach to INC’s process for oncology-related clinical trials. Most recently, Dr. Hamilton served as the chief medical officer (CMO) at Avalon Pharmaceuticals. David SPAIGHT Former MDS President Joins WIL Research as CEO WIL Research Company, a privately held global CRO and provider of drug development and chemical and food safety services, has named David Spaight CEO. Mr. Spaight oversees the company’s four major businesses — WIL Research Laboratories, Notox, Midwest BioResearch, and QS Pharma — and continues to implement a long-term strategy of integrating the businesses to provide greater value and full service to their clients worldwide. Mr. Spaight has more than 25 years of experience in the life and analytical sciences industry and most recently served as president of MDS Pharma Services. He received an MBA from the University of Michigan. Hans THUNEM Harlan Laboratories Appoints CEO Harlan Laboratories, a contract research organization and research models and services company, has promoted Hans Thunem to CEO from his previous role as the company’s group pres Harlan Laboratories, a contract research organization and research models and services company, has promoted Hans Thunem to CEO from his previous role as the company’s group president of research models and services business. Mr. Thunem holds a master’s degree in health sciences from the University of Toronto. Media POOL Dina CONWAY Quadrant HealthCom Announces Sales Promotion Quadrant HealthCom (QHI), a multimedia healthcare communications company, has promoted Dina Conway to director of content sales and assistant sales director of custom programs. Ms. Conway retains responsibility for selling Mayo Clinic Proceedings reprints and handling all international licensing opportunities across the QHI portfolio. Additionally, she is also working to help identify reprint sales opportunities for other QHI publications. Service POOL Melissa CABRAL MediciGlobal Strengthens Project Management Team MediciGlobal, a company that markets clinical trials to patients and healthcare professionals, has appointed Melissa Cabral account manager. As part of MediciGlobal’s project management team, Ms. Cabral guides clients’ clinical teams in assessing the impact of study design on patient recruitment, developing recruitment strategies that motivate patients to participate in clinical research, and overseeing the implementation of domestic and global patient recruitment programs. Ms. Cabral has worked with the New York University School of Medicine’s Aging and Dementia Research Center, the University of Pennsylvania Cancer Center, Fox Chase Cancer Center, and, most recently, a major clinical research organization. She received an M.A. in biopsychology from City University of New York. Mani CHIDAMBARAM Preceptiv Adds Business Development Director Preceptiv Learning Solutions, an inVentiv Health company and full-service training and development unit, has named Mani Chidambaram executive director, business development. Mr. Chidambaram brings to Preceptiv more than 18 years of pharmaceutical and biotech industry experience and most recently served as a performance consultant with Intelli-Media. Dr. Anthony CHILTON Bioanalytical Systems Names Chief Executive Bioanalytical Systems (BASi) has named Anthony Chilton, Ph.D., president and CEO. Dr. Chilton has served as BASi’s chief operating officer since December 2008 and interim president since January 2010. He received a Ph.D. in analytical chemistry from the University of Hertfordshire in the United Kingdom. BASi is a pharmaceutical development company providing contract research services and monitoring instruments to drug development companies and medical research organizations worldwide. Michael MICKENS Lauren STEWART Sentrx Adds Development, Quality VPs Sentrx, a provider of pharmacovigilance services to the life-sciences industry, has appointed Michael Mickens VP, commercial development. Mr. Mickens’ initial focus is on expanding the commercial solutions team and building a framework for all Sentrx services. Mr. Mickens’ 20-year career has included stints as VP of sales and marketing at etrials, VP of sales and business development in Cerner’s life-sciences division, and VP of worldwide sales and business development at QED Solutions. In other moves, Lauren Stewart has joined Sentrx as VP, quality standards and corporate compliance, with specific focus on quality management and global regulatory compliance, integrated CAPA management, document management, and training. An expert with FDA regulations pertaining to information systems, Ms. Stewart has spent the past 13 years with Cegedim Dendrite. Technology POOL Lauren BARNETT NXLevel Solutions Hires Compliance Specialist NXLevel Solutions, a developer of technology-based learning solutions, has named Lauren Barnett pharmaceutical compliance specialist. Ms. Barnett is responsible for market research and aligning the company’s PharmaCertify compliance training curriculum with the evolving regulatory requirements of the healthcare industry. She previously served as manager, ethics, and compliance training, for Stiefel Laboratories. Alan HORGAN Firecrest Clinical Names CEO Firecrest Clinical, an e-technology solution provider, has appointed Alan Horgan CEO. Mr. Horgan has worked with Firecrest since 2009 to establish operations in the United States and to globalize its business. He was group VP, late-stage development, for MDS Pharma Services, and corporate senior VP and president, clinical development, for Covance. Beverly HUDSON Stephen JOHNSON Kenneth LIGHT OmniComm Enhances Management Team OmniComm Systems, a global provider of e-clinical solutions and services, has named Beverly Hudson senior VP of business development. Ms. Hudson joins OmniComm from Medpoint Communications, where she was VP and general manager of the company’s research services group. OmniComm has promoted Chief Operating Officer Stephen Johnson to the additional role of president. Mr. Johnson joined OmniComm in 2006 and was most recently chief operating officer and executive VP of business development. Additionally, Kenneth Light was promoted to executive VP of operations from senior VP of professional services. Angela MICCOLI Cegedim Dendrite Names Head of Americas Region Cegedim Dendrite, a global provider of pharmaceutical-specific customer relationship management (CRM) solutions, has appointed Angela Miccoli president, Americas. Ms. Miccoli is responsible for overseeing all operations in the United States, Canada, and Latin America. Ms. Miccoli has been with Cegedim for 16 years, most recently serving as senior VP, global business development. She received an MBA from Clemson University. Chris TAMA Qforma Hires Business Development VP Qforma, a healthcare data analytics and predictive modeling company, has named Chris Tama senior VP, business development. Mr. Tama has 25 years of experience in biopharmaceutical and healthcare marketing on the client and agency sides, most recently as president of Ferguson. Charlie WALKER Cadient Appoints Operating Officer Cadient Group, a provider of digital marketing services and technology-enabled solutions for the healthcare industry, has named Charlie Walker chief operating officer. Mr. Walker is responsible for advancing the strategic and operational leadership of Cadient’s business network and overseeing the overall quality and delivery of solutions and services. Mr. Walker was previously chief operating officer of G2 Interactive. He holds an MBA from Rutgers University. F Send your personnel announcements to feedback@pharmavoice.com.

Posted in:

Post a Comment

You must be logged in to post a Comment.